Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Binimetinib (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 Planned initiation date changed from 28 Jul 2017 to 28 Oct 2017.
- 22 May 2017 Planned initiation date changed from 28 Apr 2017 to 28 Jul 2017.